ESTABLISHMENT LABS HOLDINGS INC. reported nine-month revenue of $199.4 million, up 36.2%, while net losses narrowed to $35.8 million from $48.4 million. Cash was $75.8 million as of September 30, 2026, and FDA approved additional smaller Motiva implant sizes.
ESTA · Establishment Labs Holdings Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Establishment Labs reported third-quarter revenue of $72 million, up 33.9% year-over-year, adjusted EBITDA of $6.4 million and free cash flow of $5.1 million. It raised 2026 revenue guidance to more than $274 million and expects 25% revenue growth in 2027.
Establishment Labs Holdings Inc. reported third-quarter revenue of $72.0 million, up 33.9%, adjusted EBITDA of $6.4 million and free cash flow of $5.1 million, its first positive quarter; full-year revenue guidance increased to more than $274 million.
Establishment Labs Holdings Inc.’s NuSil agreement amendment takes effect January 1, 2027, extending the term from December 31, 2026 to December 31, 2031, with up to five one-year renewals and revised payment, exclusive-supply, continuity and intellectual property provisions.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 29, 2026TL;DR. Q3 revenue rose 33.9% to $72.0 million, led by 119.0% U.S. growth; adjusted EBITDA expanded, the company posted its first positive operating and free cash flow, and management raised full-year revenue and minimally invasive revenue guidance. Product approvals and reconstruction progress support growth, but GAAP gross-margin pressure, lower full-year adjusted gross-margin guidance, higher GAAP operating expenses, seasonally lower sequentially minimally invasive revenue, Middle East weakness, and continuing GAAP losses remain headwinds; management expects 25% revenue growth and positive free cash flow in 2027.
- + Q3 revenue increased 33.9% to $72.0 million, driven by 119.0% U.S. growth.
- + The company generated its first positive quarter of operating cash flow and free cash flow.
- + Adjusted EBITDA increased to $6.4 million and margin expanded to 8.9% from 2.2%.
- + Full-year 2026 revenue guidance was raised to more than $274 million from $269 million to $271 million.
- − GAAP gross margin declined to 69.1% from 70.1% in the prior-year quarter.
- − Minimally invasive revenue declined sequentially because of summer seasonality in OUS direct markets.
- − The Middle East conflict reduced regional order levels relative to historical performance.
- − The company remained GAAP unprofitable with a $10.7 million net loss in Q3.
- − Full-year adjusted gross-margin guidance was lowered to approximately 70.7% from the prior 71.2% to 72.2% range.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $3.7M | Q2 2026 | — |
GAAP → non-GAAP reconciliationEBITDA -2.32M (the result of another reconciliation in this filing)
+3.14M Stock compensation expense & compensation paid in stock
+697K Foreign currency (gain) loss
+1.86M Third-party debt refinancing costs
+321K Restructuring charges
= Adjusted EBITDA 3.69M
|
|||
| Minimally invasive revenue | $12.1M | Q2 2026 | — |
| Motiva USA revenue | $24.7M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ESTA
this stock
Establishment Labs Holdings Inc.
|
$2.11B | -2.9% | +76.5% | — | 13.1% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 17
ESTABLISHMENT LABS HOLDINGS INC. reported nine-month revenue of $199.4 million, up 36.2%, while net losses narrowed to $35.8 million from $48.4 million. Cash was $75.8 million as of September 30, 2026, and FDA approved additional smaller Motiva implant sizes.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ESTA | +5.6% | +19.6% | -2.6% | +13.3% | -2.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.0% | +20.7% | -3.1% | +13.5% | -13.5% |